Key result
High expression of CD4+ and CD8+ tumor-infiltrating lymphocytes is associated with better prognosis and can determine the stage of cervical cancer.
Why the study?
The study was conducted to evaluate the role of CD4+ and CD8+ tumor-infiltrating lymphocytes in predicting the prognosis of cervical cancer patients and to support the discovery of new immunotherapy strategies targeting TILs.
Does immunohistochemical examination of CD4+ and CD8+ TILs and TILs immunotherapy improve clinical outcomes in cervical cancer patients compared to available chemotherapy?
Systematic Review (n=1,194)
Does immunohistochemical examination of CD4+ and CD8+ TILs and TILs immunotherapy improve clinical outcomes in cervical cancer patients compared to available chemotherapy?
Tumor-infiltrating lymphocytes (TILs), specifically CD4+ and CD8+, serve as prognostic biomarkers for cervical cancer and represent a potential target for immunotherapy.
Answers are grounded in this paper and cite their sources.
May aid prognostic staging in cervical cancer; reinforces TIL biomarkers via systematic synthesis.
Background: Tumor-infiltrating lymphocytes (TILs), mainly CD4+ and CD8 + T cells, have been extensively described in anti-tumor immunity, and knowledge of CD4+ and CD8+ T lymphocytes’ interplay in mediating the control of tumor growth exists. We use the role of TILs in predicting the prognosis of cervical cancer patients and develop the discovery of new immunotherapy strategies that specifically target TILs.Methods: A systematic review of studies carried out a histopathological and immunohistochemical examination of TILs and an immunotherapy treatment.Results: 10 articles were selected for a systematic review. Expression of TILs was associated with the progression of NIS to cervical cancer. CD4+ and CD8+ TILs can determine the stage and prognosis of cervical cancer. TILs immunotherapy is effective for all cervical cancer patients. Combination chemotherapy with anti-TILs immunotherapy and combination therapy for PD-1 and TILs was found to have a better potential for cervical cancer therapy.Conclusions: TILs can be a prognostic biomarker and a marker to predict cervical cancer.
No takes yet. Share an insight, caveat, or question.
Lubis et al. (2022) conducted a systematic review in Cervical cancer (n=1,194). CD4+ and CD8+ Tumor-Infiltrating Lymphocytes (TILs) vs. Low TILs expression was evaluated on Prognosis and stage of cervical cancer. High expression of CD4+ and CD8+ tumor-infiltrating lymphocytes is associated with better prognosis and can determine the stage of cervical cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: